| scholarly article | Q13442814 |
| P50 | author | Everett E Vokes | Q73567428 |
| P2093 | author name string | Robert Kratzke | |
| Xiaofei Wang | |||
| Martin J Edelman | |||
| Robert Christenson | |||
| Scott Jewell | |||
| Lydia Hodgson | |||
| P2860 | cites work | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 |
| Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis | Q28363910 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients | Q33183798 | ||
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil | Q34935734 | ||
| Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy | Q35793283 | ||
| Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer | Q36482542 | ||
| Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. | Q39787893 | ||
| 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. | Q40771073 | ||
| CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. | Q41229334 | ||
| Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer | Q43812726 | ||
| Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. | Q45055873 | ||
| Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. | Q46748115 | ||
| Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. | Q53402565 | ||
| Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. | Q53596494 | ||
| Vascular endothelial growth factor (VEGF) serum concentration changes during chemotherapy in patients with lung cancer | Q74011021 | ||
| Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study | Q80811673 | ||
| Reporting recommendations for tumor marker prognostic studies | Q81236405 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 1902-1906 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | Journal of Thoracic Oncology | Q2448056 |
| P1476 | title | Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. | |
| P478 | volume | 6 |
| Q38617495 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer |
| Q37610047 | Cyclooxygenase-2 inhibitor is a robust enhancer of anticancer agents against hepatocellular carcinoma multicellular spheroids |
| Q52576035 | Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer. |
| Q86531783 | High circulating VEGF level predicts poor overall survival in lung cancer |
Search more.